AR073949A1 - Agonistas del receptor aril-gpr120 y usos de los mismos - Google Patents

Agonistas del receptor aril-gpr120 y usos de los mismos

Info

Publication number
AR073949A1
AR073949A1 ARP090104033A ARP090104033A AR073949A1 AR 073949 A1 AR073949 A1 AR 073949A1 AR P090104033 A ARP090104033 A AR P090104033A AR P090104033 A ARP090104033 A AR P090104033A AR 073949 A1 AR073949 A1 AR 073949A1
Authority
AR
Argentina
Prior art keywords
group
substituted
6alkyl
6alkynyl
independently selected
Prior art date
Application number
ARP090104033A
Other languages
English (en)
Inventor
Aaron Novack
Jiangao Song
Dong-Fang Shi
Jingyuan Ma
Zuchun Zhao
Phuongly Pham
Xin Chen
Imad Nashashibi
Christopher Rabbat
Yun-Jung Choi
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41480108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073949(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of AR073949A1 publication Critical patent/AR073949A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen agonistas aril-GPR120. Estos compuestos son de utilidad para el tratamiento de enfermedades metabolicas, incluyendo diabetes Tipo II y las enfermedades asociadas con un control pobre de la glucemia. Reivindicacion 1: Un compuesto caracterizado porque responde a la Formula (1) o una sal farmacéuticamente aceptable del mismo, donde Q representa un grupo arilo monocíclico o bicíclico de entre 5 y 10 miembros, un grupo heteroarilo monocíclico o bicíclico de ente 5 y 10 miembros, un grupo cicloalquilo monocíclico o bicíclico de entre 5 y 10 miembros, un grupo heterocicloalquilo monocíclico o bicíclico de entre 5 y 10 miembros, o un grupo bicíclico de entre 8 y 10 miembros donde un arilo o un anillo heteroarilo de 5 o 6 miembros está fusionado a un anillo cicloalquilo o heterocicloalquilo de 5 o 6 miembros; E1, E2 y E3 se seleccionan en forma independiente entre el grupo que consiste en C, N y S; E4 se selecciona entre el grupo que consiste en C y N; X se selecciona entre el grupo que consiste en -CH2-, -C(O)- y -C(O)CH2-; Y se selecciona entre el grupo que consiste en -CH2-, -NH- y -O-; Z se selecciona entre el grupo que consiste en -(CR4R5)n-, -S-, -C(O)- y -CR4=CR5-; V se selecciona entre el grupo que consiste en un enlace, -(CR4R5)n-, -CR4=CR5-, y -O-CR4R5-; W se selecciona entre el grupo que consiste en H, C1-6alquilo y C1-6alquilo sustituido; R1 se selecciona en forma independiente entre el grupo que consiste en halo, C1-6alquilo, C1-6alquilo sustituido, C3-7cicloalquilo, C3-7cicloalquilo sustituido, C2-6alquenilo, C2-6alquenilo sustituido, C2-6alquinilo, C2-6alquinilo sustituido, CN, -ORa, -NRaRb, -C(O)Ra, -C(O)ORa, -NRaC(O)Rb, -SRa, -S(O)Ra y -S(O)2Ra; R2 se selecciona en forma independiente entre el grupo que consiste en halo, C1-6alquilo, C1-6alquilo9 sustituido, C3-7cicloalquilo, C3-7cicloalquilo sustituido, C2-6alquenilo, C2-6alquenilo sustituido, C2-6alquinilo, C2-6alquinilo sustituido, ariloxi, ariloxi sustituido, CN, -ORa, -NRaRb, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, -NRaC(O)Rb, -SRa, -S(O)Ra y -S(O)2Ra; cada uno de Ra y Rb se selecciona en forma independiente entre el grupo que consiste en H, C1-6alquilo, C1-6alquilo sustituido, C3-7cicloalquilo, C2-6alquenilo y C2-6alquinilo; R4 se selecciona en forma independiente entre el grupo que consiste en H, halo, C1-6alquilo, C1-6alquilo sustituido, C1-6alcoxi y C1-6alcoxi sustituido; R5 se selecciona en forma independiente entre el grupo que consiste en H, halo, C1-6alquilo, C1-6alquilo sustituido y C1-6alcoxi; R6 se selecciona entre el grupo que consiste en halo, C1-6alquilo, C1-6alquilo sustituido, C1-6alcoxi, C1-6alcoxi sustituido, arilo, arilo sustituido, heteroarilo y heteroarilo sustituido; opcionalmente R4 y R5 se ciclizan para formar un anillo C3-7 saturado o un grupo espiro C3-7cicloalquilo; el subíndice b es 0, 1, 2, 3 o 4; el subíndice g es 0, 1 o 2; y el subíndice n es en forma independiente 1, 2 o 3.
ARP090104033A 2008-10-21 2009-10-20 Agonistas del receptor aril-gpr120 y usos de los mismos AR073949A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10731408P 2008-10-21 2008-10-21

Publications (1)

Publication Number Publication Date
AR073949A1 true AR073949A1 (es) 2010-12-15

Family

ID=41480108

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104033A AR073949A1 (es) 2008-10-21 2009-10-20 Agonistas del receptor aril-gpr120 y usos de los mismos

Country Status (22)

Country Link
US (1) US20100216827A1 (es)
EP (2) EP2350016A2 (es)
JP (2) JP2012506386A (es)
KR (1) KR20110082145A (es)
CN (1) CN102186825A (es)
AR (1) AR073949A1 (es)
AU (1) AU2009307656B2 (es)
BR (1) BRPI0920237A2 (es)
CA (1) CA2740366A1 (es)
CL (1) CL2011000899A1 (es)
CO (1) CO6382155A2 (es)
CR (1) CR20110201A (es)
EA (1) EA022417B1 (es)
EC (1) ECSP11010989A (es)
IL (1) IL212144A0 (es)
MX (1) MX2011004125A (es)
NI (1) NI201100075A (es)
NZ (1) NZ592603A (es)
TW (1) TW201020241A (es)
UA (1) UA107917C2 (es)
WO (1) WO2010048207A2 (es)
ZA (1) ZA201102815B (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
RU2576316C2 (ru) 2010-11-03 2016-02-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидная композиция, способ контроля вредителей, способ контроля эндопаразитов, эктопаразитов или обоих и способ усиления жизнестойкости растений
CN102816067A (zh) * 2011-06-09 2012-12-12 中国医学科学院医药生物技术研究所 一种4-羟基苯酰丙烯酸衍生物、其制备方法及其应用
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
MX361458B (es) 2011-08-23 2018-12-06 Asana Biosciences Llc Compuestos de pirimido-piridazinona y uso de los mismos.
KR102006039B1 (ko) 2011-10-26 2019-07-31 다우 아그로사이언시즈 엘엘씨 살충 조성물 및 그와 관련된 방법
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
WO2013104257A1 (zh) 2012-01-12 2013-07-18 江苏恒瑞医药股份有限公司 多环类衍生物、其制备方法及其在医药上的应用
EP2805718B1 (en) 2012-01-17 2018-04-04 EA Pharma Co., Ltd. Heterocyclic amide derivative and pharmaceutical product containing same
IN2014MN01839A (es) * 2012-02-28 2015-07-03 Piramal Entpr Ltd
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
RU2623233C2 (ru) 2012-04-27 2017-06-23 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и относящиеся к ним способы
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
RU2015116540A (ru) 2012-10-11 2016-12-10 Мерк Шарп И Доум Корп. Замещенные соединения спиропиперидинила, применяемые в качестве агонистов gpr120
KR101942752B1 (ko) 2012-11-05 2019-01-28 주식회사 엘지화학 Ｇｐｒ120 효능제로서의 티오아릴 유도체
WO2014089364A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc Histone demethylase inhibitors
CA2894281C (en) 2012-12-20 2021-04-20 Inception 2, Inc. Triazolone compounds and uses thereof
KR102422559B1 (ko) 2013-03-14 2022-07-18 얀센 파마슈티카 엔.브이. Gpr120의 작용제로서 유용한 벤조 융합된 헤테로사이클릭 유도체
JP6333355B2 (ja) 2013-03-14 2018-05-30 ヤンセン ファーマシューティカ エヌ．ベー． Ｇｐｒ１２０のアゴニストとして有用な二環式ピロール誘導体
WO2014159054A1 (en) 2013-03-14 2014-10-02 Janssen Pharmaceutica Nv Gpr120 agonists for the treatment of type ii diabetes
CA2912747C (en) 2013-06-27 2021-05-04 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN105636441B (zh) 2013-10-17 2018-06-15 美国陶氏益农公司 制备杀虫化合物的方法
CA2925914A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
JP2016536295A (ja) 2013-10-17 2016-11-24 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
MX2016004946A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Procesos para la preparacion de compuestos plaguicidas.
KR20160072155A (ko) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
MX2016004948A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Procesos para la preparacion de un compuesto pesticida.
CN105636445B (zh) 2013-10-17 2018-12-07 美国陶氏益农公司 制备杀虫化合物的方法
RU2656391C2 (ru) 2013-10-22 2018-06-05 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и связанные с ними способы
US9788546B2 (en) 2013-10-22 2017-10-17 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
KR20160074621A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
RU2656888C2 (ru) 2013-10-22 2018-06-07 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и связанные с ними способы
AR098091A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones pesticidas sinérgicas y métodos relacionados
AR098105A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y métodos relacionados
MX2016005308A (es) 2013-10-22 2016-08-08 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
US9155304B2 (en) 2013-10-22 2015-10-13 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AR098092A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas sinérgicas y los métodos relacionados
CA2927206A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105828611A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 协同杀虫组合物和相关方法
MX2016005319A (es) 2013-10-22 2016-08-12 Dow Agrosciences Llc Composiciones pesticidas y metodos relacionados.
NZ720113A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AU2014340407B2 (en) 2013-10-22 2017-05-04 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
JP2016535022A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 農薬組成物および関連する方法
JP2016538265A (ja) 2013-10-22 2016-12-08 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
TWI651049B (zh) 2013-10-22 2019-02-21 陶氏農業科學公司 殺蟲組成物及相關方法
DK3107901T3 (da) 2014-02-19 2020-06-22 Piramal Entpr Ltd Forbindelser til brug som gpr120 agonister
CA2941445A1 (en) * 2014-03-07 2015-09-11 Janssen Pharmaceutica Nv Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes
CA2941442C (en) * 2014-03-07 2022-01-11 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of gpr120
US9067898B1 (en) 2014-03-07 2015-06-30 Janssen Pharmaceutica Nv Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
US8912227B1 (en) 2014-03-07 2014-12-16 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of GPR120
US10273230B2 (en) 2014-07-25 2019-04-30 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
US9249122B1 (en) 2014-07-31 2016-02-02 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
EP3186229A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
CA2954345A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
HRP20220522T1 (hr) 2014-08-04 2022-06-10 Nuevolution A/S Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
WO2016028328A1 (en) 2014-08-19 2016-02-25 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2016038540A1 (en) * 2014-09-11 2016-03-17 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
AR098113A1 (es) 2014-09-12 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
AR103264A1 (es) 2014-12-23 2017-04-26 Axikin Pharmaceuticals Inc Derivados de 3,5-aminopirazol como inhibidores de quinasa rc
AU2015367977B9 (en) * 2014-12-24 2020-02-06 Lg Chem, Ltd Biaryl derivative as GPR120 agonist
WO2016125182A1 (en) 2015-02-05 2016-08-11 Piramal Enterprises Limited Compounds containing carbon-carbon linker as gpr120 agonists
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CN104610156A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和腈基苯类gpr119激动剂、制备方法及其用途
CN104557717A (zh) * 2015-02-13 2015-04-29 佛山市赛维斯医药科技有限公司 酰肼类gpr119激动剂、制备方法及其用途
CN105272889B (zh) * 2015-07-30 2017-11-24 四川大学 一种人造革用环保低碳发泡剂及其制备方法
US9908873B2 (en) 2015-08-12 2018-03-06 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
US9856245B2 (en) 2015-08-12 2018-01-02 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
US9920040B2 (en) 2015-08-12 2018-03-20 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
CN106478616B (zh) * 2015-08-27 2020-05-12 江苏恒瑞医药股份有限公司 一种gpr40激动剂的结晶形式及其制备方法
WO2017201683A1 (en) * 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
CA3026512A1 (en) 2016-06-13 2017-12-21 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN110121343B (zh) * 2016-09-12 2023-11-03 整体健康 用作gpr120调节剂的双环化合物
US10800773B2 (en) 2016-09-12 2020-10-13 Integral Health, Inc. Monocyclic compounds useful as GPR120 modulators
US10233155B2 (en) 2016-12-29 2019-03-19 Dow Agrosciences Llc Processes for the preparation of pesticide compounds
WO2018125815A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
WO2018170067A1 (en) * 2017-03-14 2018-09-20 Dana-Farber Cancer Institute, Inc. Small molecule sensitization of bax activation for induction of cell death
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
CN109420175A (zh) * 2017-09-01 2019-03-05 任洁 基于cox的血糖调节机制
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
PL3697785T3 (pl) 2017-10-18 2023-08-07 Jubilant Epipad LLC Związki imidazopirydynowe jako inhibitory pad
JP7279057B6 (ja) 2017-11-06 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１活性化の阻害剤としてのピリミジン誘導体
LT3704120T (lt) 2017-11-24 2024-06-25 Jubilant Episcribe Llc Heterocikliniai junginiai kaip prmt5 inhibitoriai
CN112105610B (zh) * 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
CN111868035A (zh) * 2018-03-15 2020-10-30 阿克萨姆股份公司 取代的吡唑ffa4/gpr120受体激动剂
EP4360632A3 (en) 2019-01-15 2024-06-19 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3927683A1 (en) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Solid forms of fxr agonists
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
CN112876352A (zh) * 2021-01-15 2021-06-01 南京艾美斐生物医药科技有限公司 一种gpr120蛋白受体抑制剂及其制备和应用
CN115572223A (zh) * 2022-10-17 2023-01-06 聊城大学 一种苯丙酸衍生物及其用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US639527A (en) 1894-11-30 1899-12-19 Frank B Cook Drop-restoring device for telephone-switchboards.
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3300795A1 (de) * 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Substituierte 4-imidazolyl-pyrazole, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel
US5032577A (en) 1986-12-31 1991-07-16 Abbott Laboratories Peptidylaminodiols
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CZ293211B6 (cs) * 1995-02-13 2004-03-17 G. D. Searle & Co. Corporate Patent Dept. Substituované izoxazoly pro léčení zánětů
DE19648793A1 (de) * 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
JPH11263775A (ja) * 1997-09-08 1999-09-28 Sankyo Co Ltd ヒドロキシアニリン誘導体
JP3694774B2 (ja) * 1997-10-31 2005-09-14 大鵬薬品工業株式会社 フェニルカルボン酸誘導体
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
HUP0104038A3 (en) * 1998-11-09 2002-07-29 Black James Foundation Gastrin and cholecystokinin receptor ligand imidazole derivatives pharmaceutical compositions containing them and process for their preparation
AU7073400A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
ATE381542T1 (de) * 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
ATE415160T1 (de) * 2002-02-25 2008-12-15 Lilly Co Eli Modulatoren von peroxisome proliferator- aktivierten rezeptoren
WO2003099793A1 (en) * 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
WO2004011445A1 (ja) 2002-07-31 2004-02-05 Nippon Soda Co.,Ltd. アミノサリチル酸アミド誘導体、製造法及び農園芸用殺菌剤
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
MXPA05004743A (es) * 2002-11-08 2005-08-03 Hoffmann La Roche Derivados 4-alcoxioxazol sustituidos como agonistas ppar.
EP1562915A1 (en) * 2002-11-22 2005-08-17 SmithKline Beecham Corporation Farnesoid x receptor agonists
GB0228417D0 (en) * 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
US7504433B2 (en) * 2003-01-06 2009-03-17 Eli Lilly And Company Thiophene derivative PPAR modulators
PA8594401A1 (es) * 2003-02-21 2004-09-16 Pfizer Acidos carboxilicos de heteroarilo condensado como agonista del ppar
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
JP4235505B2 (ja) * 2003-08-08 2009-03-11 高周波熱錬株式会社 等速自在継手の外輪の内表面の焼入れ方法
US7470807B2 (en) * 2003-08-14 2008-12-30 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivatives and use thereof
CN100404088C (zh) * 2003-09-17 2008-07-23 张荣士 复合式棒球棒
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
WO2005051890A1 (en) * 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
WO2005054213A1 (ja) * 2003-12-02 2005-06-16 Shionogi & Co., Ltd. ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
AU2004311909A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivative as PPAR modulators for the treatment of diabetes
EP1737809B1 (en) * 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2005087710A1 (ja) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
ATE427941T1 (de) * 2004-07-27 2009-04-15 Astellas Pharma Inc Thiazolderivate mit vap-1-hemmender wirkung
US20080051418A1 (en) * 2004-11-26 2008-02-28 Tsuyoshi Maekawa Arylalkanoic Acid Derivative
US8153694B2 (en) * 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1940767A2 (en) * 2005-09-07 2008-07-09 Plexxikon, Inc. Pparactive compounds
JP2007230909A (ja) * 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
EP2001844A2 (en) * 2006-03-14 2008-12-17 Amgen, Inc Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2007140183A1 (en) * 2006-05-24 2007-12-06 Eli Lilly And Company Fxr agonists
US8183275B2 (en) * 2006-10-20 2012-05-22 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
JP5399262B2 (ja) * 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
US8394841B2 (en) * 2007-02-22 2013-03-12 Irm Llc Compounds and methods for modulating G protein-coupled receptors
MX2009008998A (es) * 2007-02-23 2009-09-02 Lilly Co Eli Moduladores del receptor activado por proliferador de peroxisoma.
WO2008108602A1 (en) * 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
AU2008333320B2 (en) * 2007-12-04 2012-12-20 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
DK2227467T3 (en) * 2007-12-04 2015-01-19 Hoffmann La Roche Isoxazolo-pyridine derivatives
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.

Also Published As

Publication number Publication date
CO6382155A2 (es) 2012-02-15
EP2690095A1 (en) 2014-01-29
EP2350016A2 (en) 2011-08-03
ECSP11010989A (es) 2011-08-31
NZ592603A (en) 2013-02-22
AU2009307656A1 (en) 2010-04-29
JP2014132037A (ja) 2014-07-17
WO2010048207A2 (en) 2010-04-29
CN102186825A (zh) 2011-09-14
TW201020241A (en) 2010-06-01
ZA201102815B (en) 2012-06-27
CA2740366A1 (en) 2010-04-29
KR20110082145A (ko) 2011-07-18
CR20110201A (es) 2011-08-29
MX2011004125A (es) 2011-05-19
AU2009307656B2 (en) 2015-07-02
BRPI0920237A2 (pt) 2015-12-29
EA201170504A1 (ru) 2011-12-30
EA022417B1 (ru) 2015-12-30
WO2010048207A3 (en) 2010-06-17
NI201100075A (es) 2012-03-15
JP2012506386A (ja) 2012-03-15
US20100216827A1 (en) 2010-08-26
CL2011000899A1 (es) 2011-09-30
IL212144A0 (en) 2011-06-30
UA107917C2 (ru) 2015-03-10

Similar Documents

Publication Publication Date Title
AR073949A1 (es) Agonistas del receptor aril-gpr120 y usos de los mismos
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
CL2020003260A1 (es) Compuestos de naftiridinona sustituidos útiles como activadores de células t
CO2017005992A2 (es) Compuestos de triazolopirimidina y usos de los mismos
PE20160208A1 (es) Compuestos de pirimidinodiona contra estados cardiacos
CU24385B1 (es) Compuestos éteres de arilo útiles para tratar cancer de célula renal
CL2022000485A1 (es) Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
PE20141191A1 (es) Compuestos como inhibidores de bace
PE20161243A1 (es) Compuesto heterociclico fusionado
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
PE20120645A1 (es) Inhibidores de epoxicetona proteasa de tripeptidos cristalinos
CL2012000953A1 (es) Procedimientos de preparacion de derivados espiro[furo[2,3-f][1,3]benzodioxol-7,3`-indol]-2`(1`h)-onas.
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
ECSP014067A (es) Activadores de fenil glucoquinasa para-aril o heterociclico sustituida
PE20190806A1 (es) Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
CL2009001044A1 (es) Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades.
PE20161476A1 (es) Derivados de indolin-2-ona o pirrolo-piridin-2-ona
AR094527A1 (es) Derivados de poliglicol bis-[3-(7-ter-butil-2-oxo-3-fenil-3h-benzofuran-5-il)-propanoilo] como estabilizantes de material orgánico
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
AR110119A1 (es) Proceso para la purificación de pirazolpiridazinas
AR059190A1 (es) Composiciones pesticidas a base de derivados de 3 - piridilo, semillas y metodos de control de plagas y de proteccion de plantas en crecimiento que las utilizan, derivados de 3-piridilo, procedimientos para su preparacion y mezclas pesticidas sinergicas que los utilizan como principio activo.
PE20191488A1 (es) Activador de nrf2
PE20170949A1 (es) Espiroindolinas para el tratamiento y profilaxis de infeccion por virus respiratorio sincitial (rsv)
CL2019001406A1 (es) Moduladores de ror gamma (rory).

Legal Events

Date Code Title Description
FB Suspension of granting procedure